Zhu Jun

39PUBLICATIONS
78CO-AUTHORS
Cardiovascular medicine and haematology not elsewhere classifiedPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jun 26, 2026
Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study.

|May 21, 2026
Mutation Profiling, Efficacy Monitoring, and Prognosis Evaluation Using Circulating Tumor DNA in Peripheral T-Cell Lymphoma: A Prospective, Multicenter, Observational Study.

|Feb 24, 2026
Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults.

Yan Xie, Ke-Shu Zhou, Lan-Fang Li

|Jan 15, 2026
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model-Based Cost-Effectiveness Analysis.

Jing Yang, Qiu-Zi Zhong, Li-Ting Qian

|Sep 01, 2025
Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study.

Yuqin Song, Dehui Zou, Haiyan Yang

|Aug 14, 2025
Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults.

Yan Xie, Ke-Shu Zhou, Lan-Fang Li

Pageof 7

Frequent Collaborators

7 joint publications

Yuqin Song

5 joint publications

Keshu Zhou

4 joint publications

Weiping Liu

4 joint publications

Dehui Zou